This medication is commonly used as a targeted therapy for cancers that overexpress the HER2 protein. It supports the management of the condition's progression. This therapy is applied to patients diagnosed with early-stage or locally advanced breast cancer, metastatic breast cancer, and advanced adenocarcinoma of the stomach or gastroesophageal junction, provided the tumors exhibit HER2 protein overexpression.

Treatment of HER2-Positive Malignancy

This treatment is applied in addressing diseases characterized by symptoms related to systemic imbalance. The main purpose is to play a role in managing the risk of the condition recurring and supports the management of long-term disease progression in early-stage disease. For metastatic malignancy, the medication is used for managing the disease and may assist with managing its progression. This targeted approach is relevant for easing the overall systemic burden of the disease and assists with maintaining functional stability.

---

Quick Fact: Relief for Disease Progression

This therapy contributes to the management of long-term disease symptoms and provides support that helps ease the overall symptom load associated with advanced, spreading cancer.

Eligibility Map: Who Can and Cannot Use Trastuzumab

Official regulatory documents strictly define Trastuzumab eligibility based on specific patient characteristics and comorbidities.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adult patients with tumors confirmed to have HER2 protein overexpression or gene amplification (mandatory patient selection via an approved test).
Populations for whom use is contraindicated	Patients with known hypersensitivity to Trastuzumab or its excipients. Also, the EMA label contraindicates use in patients with severe dyspnea at rest due to advanced malignancy or those requiring supplemental oxygen therapy.
Condition-specific eligibility rules	Eligibility is restricted by cardiac function. Treatment must be withheld or discontinued upon a clinically significant decrease in Left Ventricular Ejection Fraction (LVEF) or development of symptomatic heart failure.
Age-related eligibility rules	Approved for Adults. Pediatric use (patients under 18 years) has not been established for all approved indications.
Pregnancy and lactation eligibility status	Not recommended during pregnancy due to documented risk of embryo-fetal toxicity, including oligohydramnios. Use is not recommended during lactation. Females of reproductive potential must use effective contraception during and for seven months following treatment.

Connection to the overall eligibility profile

The eligibility profile establishes an absolute requirement for HER2-positive tumor status and requires the exclusion of patients with hypersensitivity to the drug. Use is conditional on cardiac health, with mandatory LVEF assessment before and during therapy. These limitations define who can be considered for treatment, based strictly on official regulatory classification.

Interactions with other medicines and products

Official regulatory information for Trastuzumab focuses on specific combinations and procedural constraints, particularly regarding cardiac risk and product substitution.

---

Interaction Scope

• Medicinal Product Categories with Documented Interactions: Anthracyclines (a class of chemotherapy agents, such as doxorubicin or epirubicin).
• Specific Interacting Medicines (Restrictions): Ado-trastuzumab emtansine and Fam-trastuzumab deruxtecan.
• Mechanistic Basis of Interactions: Pharmacodynamic interaction with anthracyclines leading to an increased risk of cardiac dysfunction (decreased Left Ventricular Ejection Fraction).

---

Official Interaction Statements

Interaction-Context Constraint	Regulatory Statement
Concurrent Anthracycline Use	The highest incidence and severity of cardiac dysfunction occur when administered with anthracycline-containing regimens.
Sequential Anthracycline Use	Patients may also be at increased risk of cardiac dysfunction when anthracyclines are given after stopping Trastuzumab.
Timing-Based Condition	Due to the drug's persistence, anthracycline-based therapy should be avoided for up to seven months after stopping Trastuzumab, if possible.
Substitution/Mixing Rule	Do not substitute Trastuzumab for, or mix with, other drugs (including specific related medicines) in the infusion bag or vial.

---

Summary

Regulatory documentation defines the product's interaction structure primarily through a pharmacodynamic constraint involving anthracyclines, which elevates the risk of cardiac dysfunction when used together or sequentially. The profile also enforces procedural constraints, explicitly prohibiting mixing the drug with other agents and restricting substitution with specific related medicines, thereby defining necessary safety requirements for use.

Trastuzumab is a humanized monoclonal antibody that functions as an antagonist selective for the Human Epidermal growth factor Receptor 2 (HER2) protein, encoded by the ERBB2 gene. The primary biological target is the extracellular domain (Subdomain IV) of the HER2 receptor protein .

The antibody exhibits preferential binding to cells that overexpress the HER2 receptor. This binding event initiates several molecular and intracellular pathways that lead to the functional suppression of the receptor.

Specifically, Trastuzumab's interaction with HER2 inhibits ligand-independent signaling by preventing HER2 homo- and hetero-dimerization, particularly with HER3. Preventing dimerization blocks the activation of the receptor's intrinsic tyrosine kinase domain. This, in turn, disrupts the activation of downstream cascades, including the RAS-RAF-MAPK pathway (regulating cell proliferation) and the PI3K-AKT pathway (regulating cell survival and anti-apoptosis).

Furthermore, the Fc domain of Trastuzumab mediates Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) by recruiting immune effector cells, such as Natural Killer (NK) cells. These effector cells recognize the Fc fragment, leading to the lysis of the HER2-expressing target cell. The resulting system-level physiological consequence is the selective modulation and elimination of cells exhibiting high HER2 expression.

How Trastuzumab is Used: Administration Guidelines

Trastuzumab is a specialized biologic agent administered under professional supervision using strictly defined methods and schedules.

---

Administration Scope

Parameter	Description
Route of Administration	Intravenous (IV) infusion or Subcutaneous (SC) injection, depending on the specific formulation used.
Dosing Principle	IV dosing is calculated based on the patient's actual body weight in mg/kg. The SC formulation is a fixed dose of 600 mg regardless of body weight.
Frequency Pattern	Treatment follows either a weekly cycle or a three-weekly (21-day) cycle.
Course Duration	In the adjuvant setting, treatment duration is typically limited to one year (52 weeks). For metastatic disease, administration continues until the disease progresses.

---

Procedural and Handling Rules

IV administration requires the lyophilized powder to be reconstituted and diluted exclusively with 0.9% Sodium Chloride Injection; Dextrose solutions must not be used. The initial IV infusion, or loading dose (4 mg/kg or 8 mg/kg), is administered slowly over approximately 90 minutes. Subsequent maintenance infusions may be reduced to 30 minutes if the initial administration was well tolerated. The SC fixed-dose is injected over a short period of 2 to 5 minutes.

If a dose is missed, standard clinical protocols specify an action based on the delay: if the interruption is more than one week, a re-loading dose must be administered before resuming the maintenance schedule. These procedural steps ensure consistency in how the medicine is delivered.

Research evidence / Overview of Studies for Trastuzumab

Evidence for Use in HER2-Positive Early-Stage and Locally Advanced Breast Cancer

Research was conducted using large, international Randomized Controlled Trials (RCTs) to evaluate the use of Trastuzumab after surgery (adjuvant) in adult women whose tumors exhibited HER2 overexpression. The main outcomes that researchers focused on were Invasive Disease-Free Survival (IDFS) and Overall Survival (OS). Studies were designed to compare treatment regimens that included Trastuzumab with standard chemotherapy or observation. Regulatory bodies examined findings across multiple large trials that documented patterns related to the incidence of disease recurrence. The available research data for certain groups, such as specific ethnic populations or those with unique comorbidities, is insufficient to draw conclusions.

Evidence for Use in HER2-Positive Metastatic Breast Cancer

For cancer that has metastasized (spread), research examined the medicine in various RCTs. The populations studied consisted primarily of adult patients. Studies monitored outcomes such as Overall Survival (OS) and Progression-Free Survival (PFS). Key regulatory trials reported measurements of these survival metrics, with data showing patterns related to the time patients remained without disease advancement. The optimal duration of continuous treatment requires ongoing investigation, as the evidence base is constantly evolving with the introduction of new therapies.

Evidence for Use in Advanced HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

The primary evidence for this condition was derived from a large, global RCT (the ToGA study). The populations studied were adult patients with advanced or metastatic adenocarcinoma. Researchers primarily measured Overall Survival (OS) and Progression-Free Survival (PFS). The pivotal trial documented patterns in survival metrics for patients receiving the medicine. The research noted heterogeneity in the HER2 expression patterns among different gastric tumor samples, which may contribute to variations in observed patient responses.

Evidence in Special Populations and Research Gaps

Research examined the medicine in subgroups of older adults; however, overall data for certain groups remains insufficient. Furthermore, the evidence is limited regarding the use of this medicine in the pediatric population. A key limitation noted across multiple studies relates to patterns observed concerning heart function. For many emerging combination regimens, comparative evidence is limited, and research continues to explore the optimal sequencing of therapies.

Key Studies & References Benefit of adjuvant trastuzumab in early-stage, trastuzumab-eligible breast cancer: final 10-year analysis of two randomised controlled trials.

Common questions about Trastuzumab (FAQ)

---

Q: Is it normal for my energy levels to get worse as Trastuzumab treatment continues?

Fatigue is documented in official product information as a very common side effect. While regulatory sources confirm that fatigue is expected, they do not specifically state whether the severity typically increases or improves as the treatment course progresses.

Q: Does Trastuzumab cause hair loss, or is that usually due to the accompanying chemotherapy?

Regulatory information indicates that hair loss (alopecia) is reported with lower frequency than with many standard chemotherapy agents. When hair loss occurs, it is generally mild.

Q: Is shortness of breath a common or serious side effect of Trastuzumab?

Shortness of breath (dyspnea) and severe lung problems (pulmonary toxicity) are classified as serious adverse reactions associated with treatment. Official warnings note that if a patient experiences signs of shortness of breath, the infusion may be interrupted and the patient requires monitoring.

Q: What are the different biosimilar brands of Trastuzumab available?

Regulatory bodies have approved multiple biosimilar products, which are biological medicines considered highly similar to the original Trastuzumab. Examples of approved biosimilars include Herzuma, Kanjinti, Ogivri, Ontruzant, and Trazimera. These products are approved for the same indications and are considered to have no clinically meaningful differences from the reference product.

Q: Is it common to experience taste changes or loss of appetite with Trastuzumab?

Yes, official product information lists both loss of appetite (anorexia) and disturbances to the sense of taste (dysgeusia) as frequently reported side effects. These are typically classified as either common or very common.

Q: Is there research evidence suggesting that a shorter course of Trastuzumab treatment is also effective?

The approved treatment duration for early-stage breast cancer is one year. Research is ongoing and actively investigating whether shorter treatment durations are as effective and safe as the approved regimen.

Q: Does Trastuzumab affect my ability to drive or operate machinery?

The official product label cautions that some reported side effects, such as dizziness and fatigue, may impair a person's ability to drive or operate machinery safely.

Q: Can Trastuzumab treatment cause joint pain, muscle aches, or bone pain?

Yes, joint pain (arthralgia) is documented as a very common adverse reaction. Other forms of musculoskeletal pain, including muscle aches and back pain, are also reported in official safety profiles.

Q: Are there any long-term side effects of Trastuzumab that can show up years later?

Official safety information notes that while many common side effects usually resolve, the potential for serious effects, particularly delayed cardiac dysfunction, requires long-term follow-up and monitoring after treatment ends.

Q: What is the connection between Trastuzumab and low white blood cell counts (neutropenia)?

Low white blood cell counts (neutropenia) are listed as a common side effect. The regulatory information indicates that the incidence of severe neutropenia is higher when Trastuzumab is given alongside myelosuppressive chemotherapy, which can increase the risk of infection.

Q: Is it typical to experience anxiety or emotional changes while undergoing Trastuzumab therapy?

Official product information lists anxiety as a common side effect. Other emotional changes, such as depression, are also documented as reported adverse effects.

Q: Can Trastuzumab affect the skin, such as causing rashes or soreness in hands and feet?

Skin rash is a reported side effect of the medicine. Localized adverse reactions, such as pain and redness at the injection site, are also specifically mentioned in the regulatory information for the subcutaneous formulation.

Q: Are there research trials currently looking at new uses or better delivery methods for Trastuzumab?

Research is ongoing, and multiple clinical trials are active. This includes studies investigating new combinations with other drugs and exploring new delivery methods or schedules for the medicine.

Q: Can Trastuzumab cause swelling of the hands, ankles, or legs (edema)?

Swelling in the hands, ankles, or legs (peripheral edema) is documented as a common side effect. Swelling should be discussed with a healthcare professional, as it is a common side effect and a possible sign of heart issues documented in the safety profile.

Q: What should I do if I miss a scheduled Trastuzumab treatment appointment?

Regulatory guidelines detail the procedures for managing a missed dose. These protocols determine if a re-loading dose is needed and when the regular schedule should be resumed.

Q: How will the doctors know if the Trastuzumab treatment is working for me?

Clinical studies evaluate the drug’s effectiveness based on outcomes like time without disease progression (PFS) and overall survival (OS). While official sources provide these endpoints, the specific tests used for monitoring response (e.g., imaging scans or blood markers) are generally not detailed in the public-facing regulatory labels.

Q: What specific cancers or tumor types is Trastuzumab approved to treat?

Trastuzumab is approved for cancers that overexpress the HER2 protein. This includes HER2-positive early-stage and metastatic breast cancer, and HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.

Q: What are the most common non-serious side effects people report while on Trastuzumab?

The most common non-serious side effects reported in official safety profiles include flu-like symptoms such as chills, fever, headache, and fatigue, as well as common gastrointestinal issues like diarrhea, nausea, and vomiting.

Q: Why does Trastuzumab carry a warning about potential heart problems (cardiotoxicity)?

Trastuzumab is associated with a risk of left ventricular dysfunction, which can lead to congestive heart failure. This risk is due to its targeted mechanism, which impacts the HER2 pathway known to play a role in the normal function of heart cells.

Q: Are the side effects of Trastuzumab permanent, or do most go away after treatment stops?

Official safety information notes that while common side effects usually resolve, serious effects like cardiac dysfunction may persist or manifest after treatment completion, necessitating long-term monitoring.

Q: Is there a higher risk of heart issues when Trastuzumab is combined with other specific chemotherapy drugs (like anthracyclines)?

Yes, the regulatory information explicitly states that the incidence and severity of cardiac dysfunction is highest when Trastuzumab is administered either concurrently with or immediately following chemotherapy regimens that contain anthracyclines.

Q: What is the difference between Trastuzumab and Trastuzumab Biosimilars (like Kanjinti, Herzuma, etc.)?

Biosimilars are highly similar versions of the original product, approved after extensive testing to ensure there are no clinically meaningful differences in safety or effectiveness. They are approved for the same indications as the reference product.

Q: Can Trastuzumab cause severe fatigue that is not relieved by rest?

Fatigue is classified as a very common side effect in regulatory documents. Although the degree of severity is not fully specified, persistent or severe fatigue should be discussed with a healthcare professional.

Q: What happens if a patient has to stop Trastuzumab treatment early due to side effects?

The official product information mandates that treatment must be discontinued or withheld if a patient experiences certain severe side effects, such as anaphylaxis or a clinically significant decline in heart function (Left Ventricular Ejection Fraction or LVEF).

Q: Are older patients (geriatric population) more likely to experience heart problems with Trastuzumab?

The official safety label explicitly notes that cardiac events may be observed more frequently in the older adult patient population compared to younger adults.

Q: Why is the dosage of intravenous (IV) Trastuzumab based on weight, but the subcutaneous injection is a fixed dose?

The regulatory documents confirm that the intravenous dose is calculated based on the patient's body weight, while the subcutaneous injection is a fixed dose for all patients. The specific scientific reasons for this difference in dosing principles are not detailed in the publicly available patient safety labels.

Q: Can Trastuzumab cause inflammation or irritation in the mouth or digestive system?

Yes, the official safety profile reports that common gastrointestinal side effects include diarrhea, nausea, and vomiting. Additionally, inflammation of the mouth and throat (stomatitis) is listed as a common adverse reaction.

How to Store and Dispose of Trastuzumab

Storage Requirements

Condition	Requirement (Unopened Vial)
Temperature	Store in a refrigerator between 2 C and 8 C.
Protection	Do not freeze. Store in the original outer carton to protect from light.
Access	Keep out of the sight and reach of children.

Stability and Handling

The reconstituted solution is stable for up to 28 days when stored at 2 C to 8 C, depending on the diluent used. Following final dilution for infusion, the product typically remains stable for 24 hours under refrigeration. The vial must be gently swirled during preparation and not shaken.

Disposal Instructions

Unused or expired Trastuzumab and related materials must be disposed of in accordance with local requirements. The medicine should not be thrown away via household waste or wastewater to protect the environment. Consult a pharmacist for proper disposal methods.